瑞信-美股-生物科技行业-美国生物科技Q1业绩预览-2020.4.9.pdf

《瑞信-美股-生物科技行业-美国生物科技Q1业绩预览-2020.4.9.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、9April2020EquityResearchAmericas

2、UnitedStatesU.S.BiotechnologyCreditSuisseBiotechQBankforQ1EarningsandSpringConferencePrepBiotechnology

3、CommentWeknowyou’rebusy!TohelpyouprepareforQ1earningsseasonandanupcomingroundofResearchAnalystsvirtualhealthcareconferences,we’vepreparedacom

4、prehensivequestionbankaswellasacatalystlistdetailingupcomingeventsacrosstheCreditSuisseU.S.BiotechnologycoverageMartinAuster,M.D.universe.Inadditiontoourtypicalquestionsoncommerciallaunchupdates,pipelineprogress,2123256573financialstanding,etc.,wehaveincludedpointedquestionsab

5、outCOVID-19anditspotentialmartin.auster@credit-suisse.comimpactsoneachcompany.Wehopethishelpsinyourprocess,pleaseletusknowifyouhaveEvanSeigermananyquestionsorfeedback.2123254463evan.seigerman@credit-suisse.comTiagoFauthAnalystBiotechnologyCompanies2123257569tiago.fauth@credit-

6、suisse.comMarkConnolly2123257576mark.connolly@credit-suisse.comThomasDealAusterCoverage2123253719thomasavery.deal@credit-suisse.comMatthewTerwelp,MD2123253493matthew.terwelp@credit-suisse.comSeigermanCoverageFauthCoverageDISCLOSUREAPPENDIXATTHEBACKOFTHISREPORTCONTAINSIMPORTANT

7、DISCLOSURES,ANALYSTCERTIFICATIONS,LEGALENTITYDISCLOSUREANDTHESTATUSOFNON-USANALYSTS.USDisclosure:CreditSuissedoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethattheFirmmayhaveaconflictofinterestthatcouldaffecttheobjectivityofthi

8、sreport.Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.9April2020TableofContentsSmid-CapBiotechTeamCoverage3Acceleron–XLRN.........................................................................................................4Alexion–ALXN

9、.............................................................................................................6AnaptysBio–ANAB.....................................................................................................10Apellis–APLS.....................................

10、.............................................................